196 related articles for article (PubMed ID: 25486586)
21. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
Vogel T; Kurth R; Norley S
J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220
[TBL] [Abstract][Full Text] [Related]
22. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
[TBL] [Abstract][Full Text] [Related]
23. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive investigation of common antibody-dependent cell-mediated cytotoxicity antibody epitopes of HIV-1 CRF01_AE gp120.
Ampol S; Pattanapanyasat K; Sutthent R; Permpikul P; Kantakamalakul W
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1250-8. PubMed ID: 22288892
[TBL] [Abstract][Full Text] [Related]
25. Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects.
Dupuy FP; Kant S; Barbé A; Routy JP; Bruneau J; Lebouché B; Tremblay C; Pazgier M; Finzi A; Bernard NF
mBio; 2019 Dec; 10(6):. PubMed ID: 31848282
[TBL] [Abstract][Full Text] [Related]
26. Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library.
Khan L; Kumar R; Thiruvengadam R; Parray HA; Makhdoomi MA; Kumar S; Aggarwal H; Mohata M; Hussain AW; Das R; Varadarajan R; Bhattacharya J; Vajpayee M; Murugavel KG; Solomon S; Sinha S; Luthra K
Sci Rep; 2017 Mar; 7():45163. PubMed ID: 28332627
[TBL] [Abstract][Full Text] [Related]
27. Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual.
Khan L; Makhdoomi MA; Kumar S; Nair A; Andrabi R; Clark BE; Auyeung K; Bhattacharya J; Vajpayee M; Wig N; Pantophlet R; Luthra K
PLoS One; 2015; 10(5):e0125575. PubMed ID: 25962059
[TBL] [Abstract][Full Text] [Related]
28. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site.
Sundling C; Li Y; Huynh N; Poulsen C; Wilson R; O'Dell S; Feng Y; Mascola JR; Wyatt RT; Karlsson Hedestam GB
Sci Transl Med; 2012 Jul; 4(142):142ra96. PubMed ID: 22786681
[TBL] [Abstract][Full Text] [Related]
29. Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals.
Carrillo J; Molinos-Albert LM; Rodríguez de la Concepción ML; Marfil S; García E; Derking R; Sanders RW; Clotet B; Blanco J
PLoS One; 2015; 10(3):e0120648. PubMed ID: 25803681
[TBL] [Abstract][Full Text] [Related]
30. Broadly Neutralizing Antibodies for HIV Eradication.
Stephenson KE; Barouch DH
Curr HIV/AIDS Rep; 2016 Feb; 13(1):31-7. PubMed ID: 26841901
[TBL] [Abstract][Full Text] [Related]
31. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection.
Kong R; Li H; Bibollet-Ruche F; Decker JM; Zheng NN; Gottlieb GS; Kiviat NB; Sow PS; Georgiev I; Hahn BH; Kwong PD; Robinson JE; Shaw GM
J Virol; 2012 Jan; 86(2):947-60. PubMed ID: 22031948
[TBL] [Abstract][Full Text] [Related]
32. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.
Falkowska E; Ramos A; Feng Y; Zhou T; Moquin S; Walker LM; Wu X; Seaman MS; Wrin T; Kwong PD; Wyatt RT; Mascola JR; Poignard P; Burton DR
J Virol; 2012 Apr; 86(8):4394-403. PubMed ID: 22345481
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes.
Doria-Rose NA; Louder MK; Yang Z; O'Dell S; Nason M; Schmidt SD; McKee K; Seaman MS; Bailer RT; Mascola JR
J Virol; 2012 Mar; 86(6):3393-7. PubMed ID: 22258252
[TBL] [Abstract][Full Text] [Related]
34. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein.
Klein F; Gaebler C; Mouquet H; Sather DN; Lehmann C; Scheid JF; Kraft Z; Liu Y; Pietzsch J; Hurley A; Poignard P; Feizi T; Morris L; Walker BD; Fätkenheuer G; Seaman MS; Stamatatos L; Nussenzweig MC
J Exp Med; 2012 Jul; 209(8):1469-79. PubMed ID: 22826297
[TBL] [Abstract][Full Text] [Related]
35. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.
Binley JM; Lybarger EA; Crooks ET; Seaman MS; Gray E; Davis KL; Decker JM; Wycuff D; Harris L; Hawkins N; Wood B; Nathe C; Richman D; Tomaras GD; Bibollet-Ruche F; Robinson JE; Morris L; Shaw GM; Montefiori DC; Mascola JR
J Virol; 2008 Dec; 82(23):11651-68. PubMed ID: 18815292
[TBL] [Abstract][Full Text] [Related]
36. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.
Hioe CE; Wrin T; Seaman MS; Yu X; Wood B; Self S; Williams C; Gorny MK; Zolla-Pazner S
PLoS One; 2010 Apr; 5(4):e10254. PubMed ID: 20421997
[TBL] [Abstract][Full Text] [Related]
37. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies.
Laal S; Burda S; Gorny MK; Karwowska S; Buchbinder A; Zolla-Pazner S
J Virol; 1994 Jun; 68(6):4001-8. PubMed ID: 7514683
[TBL] [Abstract][Full Text] [Related]
38. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.
Wu X; Yang ZY; Li Y; Hogerkorp CM; Schief WR; Seaman MS; Zhou T; Schmidt SD; Wu L; Xu L; Longo NS; McKee K; O'Dell S; Louder MK; Wycuff DL; Feng Y; Nason M; Doria-Rose N; Connors M; Kwong PD; Roederer M; Wyatt RT; Nabel GJ; Mascola JR
Science; 2010 Aug; 329(5993):856-61. PubMed ID: 20616233
[TBL] [Abstract][Full Text] [Related]
39. The development of CD4 binding site antibodies during HIV-1 infection.
Lynch RM; Tran L; Louder MK; Schmidt SD; Cohen M; ; Dersimonian R; Euler Z; Gray ES; Abdool Karim S; Kirchherr J; Montefiori DC; Sibeko S; Soderberg K; Tomaras G; Yang ZY; Nabel GJ; Schuitemaker H; Morris L; Haynes BF; Mascola JR
J Virol; 2012 Jul; 86(14):7588-95. PubMed ID: 22573869
[TBL] [Abstract][Full Text] [Related]
40. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.
Vaine M; Wang S; Liu Q; Arthos J; Montefiori D; Goepfert P; McElrath MJ; Lu S
PLoS One; 2010 Nov; 5(11):e13916. PubMed ID: 21085486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
